Utility of metabolic syndrome as a risk enhancing factor in decision of statin use.

Abstract

BACKGROUND\nStatins effectively reduce risk for atherosclerotic cardiovascular disease (ASCVD) when 10-year risk is\xa0≥\xa07.5%. In many patients at intermediate risk (7.5-<20% risk), there is uncertainty about reliability of risk assessment by current pooled cohort equations (PCE). A decision to initiate statin therapy is favored by several risk enhancing factors not employed in PCEs.\n\n\nOBJECTIVE\nThis study examines the scope of the metabolic syndrome, a risk enhancing factor, and its principal sequala, diabetes, in 26,796 US adults age 40-75 years from the NHANES survey data, 1999-2016.\n\n\nMETHODS\nThe prevalence of metabolic syndrome without diabetes (MetS+) and of diabetes (DM+) were determined for 10-year risk categories estimated to be low (<7.5%), intermediate (7.5% -< 20%) and high (≥20%). Data were weighted to account for complex study design.\n\n\nRESULTS\n90.4% of the population was free of ASCVD. In subjects projected to be at low risk by PCEs, MetS+ was present in 15.0% and 17.6% of women and men, respectively. MetS\xa0+\xa0increased to 30.6% of women and 29.6% of men at intermediate risk, and to 21.5% of women and 32.2% of men at high risk. In addition, DM+ was present in 6.1%/5.3% (F/M) of low risk individuals, 20.1%/14.8% (F/M) of intermediate risk subjects, and 44.3%/39.4% (F/M) of high-risk persons. Prevalence of both MetS+ and DM\xa0+\xa0rose progressively with age in women and men.\n\n\nCONCLUSIONS\nMetS+ and DM\xa0+\xa0are common multiplex risk factors that predispose to higher lifetime risk and support statin therapy in patients at intermediate and high risk.